04/19/2021
The assays detect current SARS-CoV-2 variants of concern including P.1, B.1.351, and B.1.1.7 by distinguishing specific mutations using reverse transcription PCR (RT-PCR)
04/01/2021
Bio-Rad has announced the launch of two ddPCR Assays for Droplet Digital PCR (ddPCR) platforms that support the development and manufacture of safe and effective cell and gene therapies.
02/24/2021
The qualitative multiplex immunoassay panel provides precise, specific, and sensitive detection of IgG antibodies against four SARS-CoV-2 antigens.
02/12/2021
Bio-Rad announced that its Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR Assay Kits were granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).
02/08/2021
Studies address how ddPCR technology is helping to alleviate an array of pain points in cell and gene therapy QC in the areas of product safety testing, QC scale-up, and contamination detection.
01/20/2021
The Western Blot Learning center provides comprehensive resources, information, and guidance to help researchers improve their experimental western blotting approaches to obtain high-quality data.
01/20/2021
Bio-Rad will chair a panel session that focuses on the current therapeutic landscape of SARS-CoV-2, the virus associated with COVID-19, and how the pandemic is in many ways transforming global medical research.
11/24/2020
Bio-Rad awarded 25 scholarships to U.S. high school and undergraduate teachers from underrepresented communities to attend the National Science Teaching Association (NSTA) virtual conference, NSTA Engage: Fall20.
11/03/2020
The kit provides a way for researchers to obtain highly sensitive and reproducible results.
10/07/2020
The PCR systems represent the next generation of Bio-Rad’s CFX Real-time PCR products that are used in research and genomic testing as well pathogen detection and infectious disease testing.